MiMedx Group Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Good morning, and thanks for joining us to have a conversation with Tim Wright, CEO; and Bob Stein, Executive Vice President, R&D of MiMedx. MiMedx is a leader in wound care and regenerative medicine. The company currently commercializes a portfolio of amniotic tissue products, bringing in nearly $250 million in annual revenues and has a portfolio of products for novel indications that could enter the market over the next 3 years.
To talk about the company's strategy for 2022 and beyond, I welcome Tim Wright and Bob Stein to this fireside chat with me. Tim and Bob, glad to see you both, and I appreciate you accepting our invitation to talk to our audience today.
Questions & Answers
So let us start talking through some of your thoughts on the commercial growth in 2022 and then about
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |